You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 1 - 10 of 12799 results
  1. 197-412

    SBC: System Planning Corp.            Topic: N/A

    DEVELOPMENT OF INNOVATIVE APPROACHES TO ENHANCING THE GROUND C3 SEGMENT SURVIVABILITY OF SPACE SYSTEMS REQUIRES A METHOD FOR MODELING THE SURVIVABILITY OF THE GROUND SEGMENTS OF SUCH SYSTEMS IN ORDER TO ALLOW COMPARATIVE EVALUATION OF APPROACHES AND SELECTION OF THE MOST EFFECTIVE ONE FOR DEVELOPMENT. SPC HAS DEVELOPED A COMPUTER MODEL OF THE PHYSICAL SURVIVABILITY OF SUCH SYSTEMS. GIVEN RELEVANT ...

    SBIR Phase I 1984 Department of DefenseAir Force
  2. A2A ADENOSINE AGONIST ADJUNCT FOR SYSTEMIC ANTHRAX

    SBC: ADENOSINE THERAPEUTICS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): This project develops A2A adenosine receptor (A2AAR) agonists as adjuncts to antibiotics for the treatment of anthrax septicemia. It responds to the urgent need for better treatment of highly lethal infections by this bioterrorism/biowarfare agent. Phase I has two aims, pharmaceutical development and documentation of efficacy in clinically relevant settings. Th ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  3. A2a Adenosine Agonist Cardiac Reperfusion Injury

    SBC: ADENOSINE THERAPEUTICS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Founded in 1999, Adenosine Therapeutics LLC (ATL) is a drug discovery and development company that has developed a family of potent and selective adenosine A2A receptor agonists. With the help of STTR funding, ATL has developed a lead adenosine A2A receptor agonist, ATL-146e, that is currently in late Phase II of clinical development for use as a coronary vaso ...

    SBIR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  4. A2a--Adenosine Agonist for Cardiovascular Imaging

    SBC: Discovery Therapeutics, Inc.            Topic: N/A

    Adenosine produces coronary vasodilation through activation of A-2a adenosine receptors. However adalso acts at A1 adenosine receptors to slow atrioventricular conduction and when injected into man ican be blocked with A1 receptor antagonists. DTI has synthesized a number of adenosine analogs that2a subtype of adenosine receptor and have identified WRC-0470 as a potent selective short acting corou ...

    SBIR Phase I 1995 Department of Health and Human Services
  5. A2A ADENOSINE AGONISTS AS NEUROPROTECTANTS

    SBC: ADENOSINE THERAPEUTICS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): The central goal of this research is to develop a new drug to prevent spinal cord reperfusion injury secondary to aortic clamping that occurs frequently during thoracic surgery. Irreversible spinal cord injury resulting in paraplegia or paraparesis is the single most devastating complication of surgery on the thoracic and thor ...

    SBIR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  6. A2A ADENOSINE AGONISTS AS NEUROPROTECTANTS

    SBC: ADENOSINE THERAPEUTICS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): The central goal of this research is to develop a new drug to prevent spinal cord reperfusion injury secondary to aortic clamping that occurs frequently during thoracic surgery. Irreversible spinal cord injury resulting in paraplegia or paraparesis is the single most devastating complication of surgery on the thoracic and thor ...

    SBIR Phase II 2002 Department of Health and Human ServicesNational Institutes of Health
  7. A2a Adenosine Agonists for Diabetic Nephropathy

    SBC: ADENOSINE THERAPEUTICS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Diabetic nephropathy (DN) accounts for approximately 40% of the cases of renal failure requiring dialysis or transplantation. Moreover, diabetic nephropathy is associated with markedly higher morbidity and mortality rates. It is important to develop novel interventions to prevent complications of diabetes. Inflammation in the genesis of diabetes, as well as its ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  8. A2a Adenosine Agonists for Diabetic Nephropathy

    SBC: ADENOSINE THERAPEUTICS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Diabetic nephropathy (DN) accounts for approximately 40% of the cases of renal failure requiring dialysis or transplantation. Moreover, diabetic nephropathy is associated with markedly higher morbidity and mortality rates. It is important to develop novel interventions to prevent complications of diabetes. Inflammation in the genesis of diabetes, as well as its ...

    SBIR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  9. A2A ADENOSINE AGONISTS LIMIT DAMAGE FROM INFECTION

    SBC: ADENOSINE THERAPEUTICS, LLC            Topic: N/A

    epsis syndrome is the 11th leading cause of death in the United States ( about 900,000 new cases per year) with a mortality of about 35 percent. The need for adjunctive therapies is urgent. In Phase I of this SBIR award we documented the anti-inflammatory effects of adenosine A2A receptor (A2AAR) agonists on isolated immune cells and have observed ramatically improved survival in mouse models of I ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  10. A2A ADENOSINE AGONISTS LIMIT DAMAGE FROM INFECTION

    SBC: ADENOSINE THERAPEUTICS, LLC            Topic: N/A

    epsis syndrome is the 11th leading cause of death in the United States ( about 900,000 new cases per year) with a mortality of about 35 percent. The need for adjunctive therapies is urgent. In Phase I of this SBIR award we documented the anti-inflammatory effects of adenosine A2A receptor (A2AAR) agonists on isolated immune cells and have observed ramatically improved survival in mouse models of I ...

    STTR Phase II 2002 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government